Company intelligence / Profile preview
Innorna
Shenzhen, Guangdong, Chinainnorna.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Other
01
Overview
Innorna has advanced multiple mRNA/LNP-based programs into clinical development. Notably, its investigational therapy IN015 for PFIC received U.S. FDA Rare Pediatric Disease Designation in late 2024. Another candidate, IN016 for PFIC targeting a different etiological factor, previously received both RPDD and Orphan Drug Designation from the FDA. The company’s pipeline also includes candidates for infectious disease vaccines and tumor immunotherapy at various stages.[3] No published pivotal trial results as of May 2025.
- Therapeutic areas
- OncologyImmunologyRare DiseasesGastroenterologyInfectious Diseases
- Modalities
- mRNA therapeuticsLipid nanoparticle (LNP) delivery systemsRNA therapies (including gene editing and cell therapy)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
BeiGene – global strategic collaboration to co-develop several mRNA-LNP projects; BeiGene receives exclusive global rights to certain candidates plus non-exclusive license to use Innorna’s proprietary LNP technology.
Beyond the preview
Go deeper on Innorna.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Innorna.